Skip to content

Tackling defective Prefrontal development in Mendelian Syndromes: a compelling (pre-) clinical integrative approach

Tackling defective Prefrontal development in Mendelian Syndromes: a compelling (pre-) clinical integrative approach - Promise

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON54120
Enrollment
150
Registered
2021-11-16
Start date
2022-11-17
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Witteveen-Kolk syndrome

Interventions

The tailor-made, non-medical intervention is designed by an experienced multidisciplinary intradisciplinary team, constitutes the regular course of action after diagnoses, also known as standard pra

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
2 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in psychiatric and neuropsychological assessment for this study, all subjects (i.e., participants with RGNS and typically developing children) must meet all of the following criteria: * Biological age above 3 years, because of reliability in diagnostic procedures. * Written informed consent. * Ability to speak Dutch. Additionally a total IQ above 50 is required to be eligible for participation the treatment fase. In addition to the inclusion criteria stated above, all participants with RGNS must meet the following criteria: - Molecular confirmed syndrome diagnosis (i.e. confirmed pathogenic defect in SIN3A, ARID1B/ARID1A/ARID2/SMARCB1/SMARCA4/SMARCE1/SOX11/SMARCC2, ANKRD11, FOXP1, MAOA or KMT2A)

Exclusion criteria

Exclusion criteria: - Subjects that also have another molecular diagnosis that is likely to contribute to their developmental phenotype - Auditory or visual handicap, unable to sit in a chair - Typical developing participants must not be diagnosed with a mental disorder by the DSM-5 classification system at time of inclusion.

Design outcomes

Primary

MeasureTime frame
- Definition of individual neurocognitive, psychopathological and behavioral profiles associated to specific RGNS.

Secondary

MeasureTime frame
- Definition of group based detailed neurocognitive, psychopathological and behavioural age-related profiles associated to specific RGNS. - Create an overview of the applicability of a set of validated, neurocognitive and behavioural tests adapted to the RGNS. - Development of tailor-made interventions that target behavioural problems, psychopathology and quality of life. - Evaluate the effect of tailor-made interventions on behavioural problems, psychopathology and quality of life. - Identify factors that predict effect of intervention.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)